Clinical Trial

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-27.
Status change: Not Yet Recruiting → Recruiting 2025-02-10
Trial Details
NCT Number NCT06293651
Lead Sponsor Dong-A ST Co., Ltd.
Conditions Locally Advanced or Metastatic Solid Tumors
Enrollment 125 participants
Start Date 2024-04-18
Primary Completion 2026-01 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-02-12